Palvella Therapeutics
PVLA
26 hedge funds and large institutions have $31.7M invested in Palvella Therapeutics in 2016 Q2 according to their latest regulatory filings, with 10 funds opening new positions, 5 increasing their positions, 5 reducing their positions, and 1 closing their positions.
900% more first-time investments, than exits
New positions opened: 10 | Existing positions closed: 1
731% more capital inflows, than outflows
Capital inflows: $5M | Capital outflows: $602K
53% more funds holding
Funds holding: 17 → 26 (+9)
2.06% more ownership
Funds ownership: 43.72% → 45.78% (+2.1%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0% more repeat investments, than reductions
Existing positions increased: 5 | Existing positions reduced: 5
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
+$2.76M |
| 2 |
Lombard Odier Asset Management (USA)
New York
|
+$1.02M |
| 3 |
BVF Inc
San Francisco,
California
|
+$462K |
| 4 |
DCM
DAFNA Capital Management
Los Angeles,
California
|
+$332K |
| 5 |
FWM
Frontier Wealth Management
Kansas City,
Missouri
|
+$163K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OFM
Omega Fund Management
Boston,
Massachusetts
|
-$424K |
| 2 |
Millennium Management
New York
|
-$89K |
| 3 |
Oppenheimer & Co
New York
|
-$85.5K |
| 4 |
Walleye Trading
New York
|
-$2.6K |
| 5 |
Tower Research Capital (TRC)
New York
|
-$920 |
PVLA Hedge Fund Activity: Q2 2016 in Review
26 of the 3,756 institutional investors tracked by Wall St. Rank reported a position in Palvella Therapeutics (PVLA) for Q2 2016, worth a combined $31.7M — down 4.1% from $33.1M a quarter earlier.
Buyers outnumbered sellers: 10 funds opened new PVLA positions and 1 closed out — a net gain of 9 holders — while 5 added to existing stakes and 5 trimmed.
The largest buyer was Sabby Management, adding an estimated $2.76M. The largest seller was Omega Fund Management, cutting an estimated $424K.
- 26 institutional investors held Palvella Therapeutics (PVLA) as of Q2 2016, up from 17 in Q1 2016.
- Funds reported $31.7M of Palvella Therapeutics stock for Q2 2016, down 4.1% quarter-over-quarter.
- 10 funds opened new Palvella Therapeutics positions in Q2 2016 and 1 closed out, a net change of +9 holders.
- The largest Palvella Therapeutics buyer in Q2 2016 was Sabby Management, an estimated $2.76M added.
- The largest Palvella Therapeutics seller in Q2 2016 was Omega Fund Management, an estimated $424K sold.
Based on aggregated 13F filings for Q2 2016.